Institute for Wealth Management’s Immix Biopharma IMMX Stock Holding History

Institute for Wealth Management’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.08M	Buy	+337,552	New	+$2.48M	0.33%	64

Other funds holding IMMX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Institute for Wealth Management's IMMX Position: Q1 2026 in Review

Institute for Wealth Management opened a new position in Immix Biopharma (IMMX) in Q1 2026: 337,552 shares worth $3.08M. The stake represents 0.33% of the portfolio and ranks #64 among its holdings.

77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

Institute for Wealth Management held 337,552 shares of Immix Biopharma worth $3.08M as of Q1 2026.
Immix Biopharma was a new Institute for Wealth Management position in Q1 2026.
Immix Biopharma made up 0.33% of Institute for Wealth Management's portfolio in Q1 2026, its #64 holding.
77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Institute for Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.